CNS Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This report of CNS Pharmaceuticals Inc is prepared by All Street Sevva using leading AI. Full ESG assessment of CNS Pharmaceuticals Inc can be accessed by signing up for free. The page contains a zero-cost E,S&G analysis covering CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 0.0, social score of 5.3 and governance score of 8.0.
4.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 868 | Trevena Inc | 4.5 | High |
| 868 | Urogen Pharma Ltd | 4.5 | High |
| 910 | CNS Pharmaceuticals Inc | 4.4 | High |
| 910 | CanBas Co Ltd | 4.4 | High |
| 910 | BMP Pharma Trading AG | 4.4 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does CNS Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes CNS Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid CNS Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas CNS Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs CNS Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes CNS Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes CNS Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for CNS Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.